Hoth Therapeutics, a biopharmaceutical company, has announced that it will buy up to $1 million worth of Bitcoin (BTC) as a treasury asset. The company cited Bitcoin's increasing adoption, institutional purchases, and its potential as a hedge against inflation as reasons for the move. Hoth's decision follows similar moves by other companies, such as MicroStrategy, and indicates growing interest from endowments, pension funds, and family offices in Bitcoin. The price of Bitcoin has reached new all-time highs, surpassing $94,000, with analysts predicting it will continue to rise in the coming months.
BIS Report Questions Decentralization of Liquidity Provision in Uniswap Amid Institutional Dominance
Metacade and SuperVerse Partner to Revolutionize On-Chain Gaming with Pool Prizes on Base Blockchain